QIAGEN N.V.

Leading molecular-diagnostics and sample-prep franchise with top-decile margins, returns and free cash flow but only mid-pack growth.

Strengths

• Net/operating margins ~89th pct, FCF margin 90th, OCF margin 94th, net income +4x (94th)
• Strong returns (ROA 89th, ROIC 85th) and a clean balance sheet (current ratio 3.9, cash 94th pct)

Risks

• Revenue growth modest at 5.7% (44th pct) and ROE 11% only mid-pack (73rd)
• Intensifying diagnostics competition (latent-TB, syndromic testing) and tariff/reimbursement pressure

Notable findings

• Customer concentration~72% of revenue from one customer/distributor — 5 billion in sales, approximately 72% of sales, in 2025 and that are expected to reach combined annual sales of approximately $2 billion by 2028
• Strong balance sheetStrong balance sheet — $1.1B cash & investments